Hot stocks from Monday's premarket 🔥

Good Morning! Hey, there! It's Chris from Elite Trade Club, here to give you this morning's premarket trading news. Happy Monday! It's September 25th. I hope you had a great weekend. Now, let's get ready to trade! Markets 📈 Stocks closed out last week with modest losses on Friday. The Dow lost 0.3%, the S&P 500 declined 0.2%, and the Nasdaq fell by less than 0.1%. The small-cap Russell 2K also suffered a 0.3% loss. Today, S&P 500 futures are down 0.1% in early premarket trading Sponsored [The AI Singularity Clock Is Ticking]( The dot-com crash… the COVID crash… but we've still never seen anything like what's next for artificial intelligence in the next few months. It's called the Singularity – and it refers to the exact millisecond when AI breaks free from its shackles to grow BILLIONS of times more powerful than humans. [Click here to get on the right side of this historic event.]( Premarket Highlights 🔎 🤝 Hollywood Writers Reach Tentative Deal On Sunday, Hollywood writers reached an agreement to end a months-long strike with a three-year deal. The deal, which includes provisions for increased writer royalties, mandatory staffing for television "writing rooms," and protections against the use of A.I. in content creation. The agreement still needs to be finalized, but it could be the early stages of a deal to end the strike. Shares of Warner Bros. [WBD] and Paramount [PARA] are up on the news. What to Watch Today 👀 Can Stocks Shake Off Fed Fever? Investors are still reeling from the revelations to come out of last week's Federal Reserve policy meeting. Stocks closed out last week on a down note, so it will be interesting to see which way the market goes today. Today's earnings and economic calendars are very thin, so this could be the trading session's most consequential storyline. Major Earnings 💰 Thor Industries, Inc. [THO] ... PM Economy 🏗 - None Running Hot 🔥 Gainers - Paxmedica [PXMD] >> +20.5% - Avalo Therapeutics [AVTX] >> +20.3% - Comscore [SCOR] >> +16.2% - Galectin [GALT] >> +20.0% Decliners - Vahanna Tech Edge [RDZN] >> (48.6%) - Brainstorm Cell Therapeutics [BCLI] >> (46.0) - MicroAlgo [MLGO] >> (29.7%) - Turbo Energy ADR [TURB] >> (18.3%) Cibus [CBUS] - Last Close: $18.10 Cibus is heating up in the wake of a personnel move. Early last week, it announced the appointment of Jim Collins, former CEO of Corteva, to its board of directors. The chair of Cibus's audit committee said, “Jim brings ... immense knowledge and strategic vision on the ... future role and use of Gene Editing in agriculture.” Collins has an impressive resume, serving in leadership positions at several notable companies, including Corteva, DowDuPont, and DuPont. CBUS is up 14.5% in today's premarket. My Take: I'm not sure what's driving CBUS's premarket move. The news mentioned above broke last Monday, so it's been a while. However, the stock could find new price support, it can hold above the $20 mark. Biophytis [BPTS] - Last Close: $0.8801 Shares of Biophytis are rebounding from a pullback. The tiny biotech lost 12.8% on Friday after French regulators requested additional data regarding an early access authorization for sarconeos for severe COVID-19. Biophytis said the regulator wants more data so it can "precisely evaluate the risk vs. reward ratio" and authorize the drug as a treatment for severe COVID. Regulators made their ruling despite the fact the drug produced statistically significant results in Phase 2 & 3 trials. Biophytis will provide results of ongoing studies and additional data from its COVA study. It plans to resubmit its application to the French regulator in Q1 2024. BPTS is one of today's top stocks with a 39.7% gain. My Take: It looks like Friday's BPTS sell-off may have been overdone. It sounds like this drug will get approved, eventually, so there could be a catalyst coming down the pipeline in Q1 2024. Eledon Pharmaceuticals [ELDN] - Last Close: $1.21 Eledon Pharma is up on the heels of an unusual press release. The company said one of its drugs was used as part of the second-ever pig-to-human transplant of a genetically modified heart. Eledon's tegoprubart was used as part of a chronic immunosuppressive regimen administered during the transplant procedure. The procedure was completed on September 20th at University of Maryland Medical Center on a 58-year-old male suffering from heart failure. Eledon Chief Executive Officer David-Alexandre C. Gros called the procedure a "momentous milestone for the transplant community." ELDN is up 19.8% on the news. My Take: ELDN could be coming off a double-bottom, and this story could give it the extra nudge it needs to break out. However, even though I like this setup, I should warn you that it's a very speculative play. Faze Holdings [FAZE] - Last Close: $0.1530 Faze Holdings is rallying after several announcements. Late last week, NASDAQ regulators sent the company a letter that extended its compliance period for an additional 180 days. FAZE now has additional time to regain compliance with Nasdaq's minimum bid requirement. Also, late last week, the company filed a prospectus for a proposed offering of its shares that was initially announced on Sept. 11th. FAZE closed out last week with a 4.4% loss, but it's rebounding in today's premarket. Shares are up 75.7%, and it's today's top premarket stock. My Take: There could be a little market magic behind this move. FAZE has struggled as of late, and sharp-eyed investors may be taking advantage of the stock's small float to set off a pump, which could be followed by a major DUMP... That's it for today! Thanks for reading, and good luck out there! Best Regards, Chris D. -- Elite Trade Club P.S... Want alerts delivered straight to your cell every morning for free?* Text ELITE to 47121 to sign up now and get our watchlists sent directly to your phone! Or text CLOSE to 47121 to get on the mobile alert list for our Closing Bell Roundup report, featuring the day's top winners and losers. *Standard message/carrier rates may apply. Legal Stuff: Stocks featured in this newsletter are for entertainment purposes only. You should not base any investment decisions on information contained in my newsletter. Stocks featured in this newsletter may be owned by owners/operators of this website which could impact our ability to remain unbiased. Please consult a financial advisor before making any trading decisions. I may earn a small commission from links placed inside of these emails. [Bots click here]( 1969 S. ALAFAYA TRAIL Orlando FL 32828 USA [Unsubscribe]( | [Change Subscriber Options](